Potential application of chitosan stabilized silver nanoparticles for simultaneous control of dengue virus and mosquito vectors

Dengue fever pandemic caused by dengue virus has been claimed for many lives, however, no specific treatment is available. Prevention based on vector control posed to be the most effective measure so far. The application of chitosan stabilized silver nanoparticle (AgNPs) to control larvae and adult mosquitoes has recently discovered, but their ability to inhibit Dengue virus has scarcely discussed. In this study, chitosan stabilized AgNPs have been prepared and tested against dengue virus type 1. The results showed that chitosan stabilized AgNPs can inhibit 96.66% and 98.33% dengue virus type 1 at 12.50 ppm and 25.00 ppm, respectively, without any toxicity to BHKFcɣ cells. This study confirms that chitosan stabilized AgNPs have a highly antiviral ability against dengue virus in addition to its mosquitocidal properties. This allows one to control both virus and vector simultaneously. The study suggested that chitosan stabilized AgNPs could be an effective tool to prevent the dengue epidemic.

Assessing evidence for avian-to-human transmission of influenza A/H9N2 virus in rural farming communities in northern Vietnam

Rural farming communities in northern Vietnam do not routinely practice vaccination for influenza A viruses (IAV) for either humans or poultry, which enables us to study transmission intensity via seroepidemiology. Using samples from a longitudinal cohort of farming households, we determined the number of symptomatic and asymptomatic human infections for seasonal IAV and avian A/H9 over 2 years. As expected, we detected virologically confirmed acute cases of seasonal IAV in humans, as well as large numbers of subclinical seroconversions to A/H1pdm [55/265 (21 %)], A/H3 [95/265 (36 %)] and A/H9 [24/265 (9 %)]. Five of the A/H9 human seroconverters likely represented true infections rather than heterosubtypic immunity, because the individuals seroconverted solely to A/H9. Among co-located poultry, we found significantly higher seroprevalance for A/H5 compared to A/H9 in both chickens and ducks [for northern study sites overall, 337/1105 (30.5 %) seropositive for A/H5 and 123/1105 (11.1 %) seropositive for A/H9].